about
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCTDifferential effects of HOXB4 on nonhuman primate short- and long-term repopulating cellsNational Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Research Methodology and Study Design Working Group Report.Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting.Costs of second allogeneic hematopoietic cell transplantation.Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trialDonor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose.Methylation profiling identified novel differentially methylated markers including OPCML and FLRT2 in prostate cancerAdjuvant Radiation Therapy and Chemotherapy in Merkel Cell Carcinoma: Survival Analyses of 6908 Cases From the National Cancer Data Base.Recombinant human macrophage colony-stimulating factor-induced thrombocytopenia in dogs.Treatment of recurrent platinum resistant ovarian or peritoneal cancer with gemcitabine and doxorubicin: A phase I/II trial of the Puget Sound Oncology Consortium (PSOC 1602).Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma.A phase I study of Topotecan, as a radiosensitizer, for thoracic malignancies.Cytopenias after day 28 in allogeneic hematopoietic cell transplantation: impact of recipient/donor factors, transplant conditions and myelotoxic drugs.Durable donor engraftment after radioimmunotherapy using α-emitter astatine-211-labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transplantationLong-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation.Donor-recipient mismatch for common gene deletion polymorphisms in graft-versus-host diseaseMarital adjustment, satisfaction and dissolution among hematopoietic stem cell transplant patients and spouses: a prospective, five-year longitudinal investigation.Low-dose total body irradiation and fludarabine conditioning for HLA class I-mismatched donor stem cell transplantation and immunologic recovery in patients with hematologic malignancies: a multicenter trialDonor statin treatment protects against severe acute graft-versus-host disease after related allogeneic hematopoietic cell transplantation.Costs of allogeneic hematopoietic cell transplantation using reduced intensity conditioning regimensLife expectancy in patients surviving more than 5 years after hematopoietic cell transplantation.Hypertension in long-term survivors of pediatric hematopoietic cell transplantation.Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testingProlonged responses in patients with MDS and CMML treated with azacitidine and etanerceptPharmacokinetic and pharmacodynamic analysis of inosine monophosphate dehydrogenase activity in hematopoietic cell transplantation recipients treated with mycophenolate mofetil.A preclinical model of double- versus single-unit unrelated cord blood transplantation.Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia.Simultaneous transplantation of hematopoietic stem cells and a vascularized composite allograft leads to tolerance.Anti-thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study.Impact of recipient statin treatment on graft-versus-host disease after allogeneic hematopoietic cell transplantation.Langerhans cell homeostasis and turnover after nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation.Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patientsImproving hematopoietic cell transplant outcomes in a new era of genomic researchRecipient pretransplant inosine monophosphate dehydrogenase activity in nonmyeloablative hematopoietic cell transplantationPathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system.Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation.Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host diseaseA randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation.Comparison of short-term response and long-term outcomes after initial systemic treatment of chronic graft-versus-host disease.
P50
Q24685958-3F447AB3-54A3-464A-B217-2BFD5BE79E1BQ27307742-F383AB98-75A4-4FE3-9516-7EB25E0B1891Q30245682-185170E7-4295-42E8-BE72-FB9073219584Q30486842-1D7A023C-7800-4646-BF17-ACB1922BC40CQ30540989-745CFD4D-BECE-4AD9-9A56-EFA56A917E69Q30543777-59DCEFA8-F25D-420D-8487-19BFB771F660Q30558271-BE283146-04DD-4AC5-89B5-890DF9793BCFQ30764223-5FEF2181-E868-459C-90E4-F2E247A43017Q31104346-711589CC-628E-49B9-BE37-7D62AB6C5BDAQ33348052-E1741AE1-CDC5-47CF-A055-E5C35C0164BEQ33348687-794A9181-D1EF-4E98-B860-9254374FB859Q33348936-3D4A73E6-E75D-4F2E-9361-6B2D79BAD89FQ33359930-4E84223F-2BC7-473F-B898-0C5224B9ABA2Q33396929-09DE4088-6787-491E-865B-1CC88FD53113Q33398529-A0EBE8B4-400F-4417-AB9F-5D1D18A2BDA1Q33419003-480A15D7-28BD-4337-B0A4-D62A8C4BB685Q33583414-BF4F7AFF-D1B3-4938-A992-26C0030C6373Q33635782-3A8B83FF-DCE0-46E2-AEBC-8F5159C8B8F1Q33653406-7DDB715D-D65C-4CF6-857F-84A3F1058582Q33677489-F6A061F4-F068-4AF5-A2AD-E38934AFD4FAQ33699602-AA312D10-32A7-4E81-8EC1-1631E28707E3Q33710708-F91BB75C-E6F3-4B13-8965-0D23BB8ADDDCQ33729496-8E738FF7-1140-4E02-A6F2-03CAAA36EB13Q33813830-49F8A4AC-774D-4519-82DB-A099011758D1Q33828803-1F4EB710-8200-47AA-B6F2-936BC92760D0Q33905541-892F1806-1A0D-4515-8BA3-409FD93650B3Q33965521-59054024-85C9-4FC5-9080-1FBBD83DD777Q33990856-3ED3157B-F354-4A44-9855-BF07E43C8F94Q34027002-4A383ECF-E1E2-4BC7-A891-EEEBC022A603Q34098328-04DEF4E2-C2FF-4B54-838E-64D28574DEFCQ34106362-989B52A3-6178-45EB-A59F-A1FEDA511E6AQ34111627-1FCE17AD-D499-49E5-8748-E6C13390F731Q34117487-47E5AE1E-A1C8-4F67-82D5-047CAC4D0BA9Q34157754-3F9B28DA-A39B-45C6-A31C-00ACDBCB3362Q34175259-8C01C069-B19C-4499-B7B3-FF194C4234F4Q34208807-B87E6684-85AF-4277-8814-1D58B10B2101Q34260505-6689265B-9D34-40B2-AA5F-8E9CA295634DQ34272547-2A81EB32-7373-4E91-B0A4-BA8FA255A19FQ34272554-A3176865-8ECD-47DD-83B3-A480C90918AEQ34279929-8AF678D5-C0E9-4B7C-9C1E-3A6B08419E54
P50
name
Barry E Storer
@en
Barry E Storer
@nl
type
label
Barry E Storer
@en
Barry E Storer
@nl
prefLabel
Barry E Storer
@en
Barry E Storer
@nl